Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Actinogen Medical Limited

Healthcare US ATGGF

0.0008USD
0.00(0%)

Last update at 2026-06-18T13:30:00Z

Day Range

0.00080.0008
LowHigh

52 Week Range

0.010.04
LowHigh

Fundamentals

  • Previous Close 0.0008
  • Market Cap113.49M
  • Volume0
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-18.05035M
  • Revenue TTM7.36M
  • Revenue Per Share TTM0.002
  • Gross Profit TTM 7.36M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -14.73226M -22.97579M -10.75227M -9.49737M -3.91507M
Minority interest - - - - -
Net income -14.73226M -13.04428M -10.75227M -9.49737M -3.91507M
Selling general administrative 2.03M 1.73M 6.57M 4.56M 3.11M
Selling and marketing expenses 6.10M 5.50M - - -
Gross profit 5.49M 9.93M - - -
Reconciled depreciation 0.42M 0.42M 0.41M 0.40M 0.39M
Ebit -15.35425M -13.25582M -10.98515M -9.53336M -3.91984M
Ebitda -15.01301M -12.92117M -10.33006M -9.07822M -3.50605M
Depreciation and amortization 0.34M 0.33M - - -
Non operating income net other - - - - -
Operating income -14.93204M -12.83899M -15.87309M -13.17344M -5.90391M
Other operating expenses 20.42M 22.77M - - -
Interest expense 0.05M 0.02M 0.02M 0.02M 0.02M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.69M 0.29M 0.37M 0.04M 0.03M
Net interest income 0.64M 0.27M 0.35M 0.02M 0.00477M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - -9.93150M - - -
Total revenue 5.49M 9.93M - - -
Total operating expenses 20.42M 22.77M - - -
Cost of revenue - - - - -
Total other income expense net 0.20M -10.13679M 4.77M 3.65M 1.98M
Discontinued operations - - - - -
Net income from continuing ops -14.73226M -13.04428M -10.75227M -9.49737M -3.91507M
Net income applicable to common shares - - -10.75227M -9.49737M -3.91507M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 24.48M 21.31M 15.21M 23.31M 18.38M
Intangible assets 1.78M 2.09M 2.41M 2.72M 3.03M
Earning assets - - - - -
Other current assets 0.13M 0.40M - - -
Total liab 6.15M 1.62M 1.80M 1.57M 0.92M
Total stockholder equity 18.34M 19.70M 13.41M 21.74M 17.46M
Deferred long term liab - - - - -
Other current liab 0.96M 0.70M 0.61M 0.50M 0.29M
Common stock 101.25M 100.02M 78.71M 76.94M 60.05M
Capital stock 101.25M 100.02M 78.71M 76.94M 60.05M
Retained earnings -96.46810M -81.73583M -68.69155M -57.93928M -48.44191M
Other liab - - - - -
Good will - - - - -
Other assets - - - - 0.04M
Cash 16.50M 9.45M 8.46M 16.37M 13.42M
Cash and equivalents - - - - -
Total current liabilities 5.96M 1.36M 1.80M 1.48M 0.76M
Current deferred revenue - - - - -
Net debt -13.23978M -9.13167M -8.37314M -16.20501M -13.18521M
Short term debt 3.08M 0.06M 0.09M 0.08M 0.07M
Short long term debt 3.01M - - - -
Short long term debt total 3.26M 0.32M 0.09M 0.17M 0.24M
Other stockholder equity - - -1.55407M -2.20422M 1.74M
Property plant equipment - - 0.11M 0.17M 0.25M
Total current assets 22.43M 18.88M 12.69M 20.42M 15.06M
Long term investments - - - - -
Net tangible assets - - 11.00M 19.02M 14.42M
Short term investments - - - - -
Net receivables 5.80M 9.43M 4.23M 4.05M 1.63M
Long term debt - - - - -
Inventory - -0.40307M - - -
Accounts payable 1.93M 0.60M 1.10M 0.90M 0.39M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 13.56M 1.41M 3.39M 2.74M 5.85M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - 0.04M
Deferred long term asset charges - - - - -
Non current assets total 2.05M 2.44M 2.52M 2.89M 3.32M
Capital lease obligations 0.26M 0.32M 0.09M 0.17M 0.24M
Long term debt total - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments -0.03802M -0.00816M -0.03660M -0.00294M -0.00619M
Change to liabilities - - 0.25M 0.69M 0.11M
Total cashflows from investing activities -0.03802M -0.00816M -0.03660M -0.00294M -0.00619M
Net borrowings 3.00M - -0.07834M -0.07117M -0.08410M
Total cash from financing activities 14.65M 17.95M 0.82M 12.42M 10.11M
Change to operating activities - - 0.06M 0.03M -0.08422M
Net income -14.73226M -13.04428M -10.75227M -9.49737M -3.91507M
Change in cash 7.05M 0.99M -7.91021M 2.95M 8.38M
Begin period cash flow 9.45M 8.46M 16.37M 13.42M 5.04M
End period cash flow 16.50M 9.45M 8.46M 16.37M 13.42M
Total cash from operating activities -7.55577M -16.95087M -8.69824M -9.51713M -1.72390M
Issuance of capital stock 12.24M 19.11M 0.90M 13.32M 10.91M
Depreciation - 0.42M 0.41M 0.40M 0.39M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables 3.50M -5.19724M -0.18167M -2.41232M 1.49M
Sale purchase of stock -0.52985M -1.06428M - -0.83129M -0.71587M
Other cashflows from financing activities -0.06067M -0.09170M -0.07834M -0.07117M -0.08410M
Change to netincome - - 1.52M 1.27M 0.29M
Capital expenditures 0.04M 0.00816M 0.04M 0.00294M 0.00619M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 3.54M -5.61559M - - -
Stock based compensation - - - - -
Other non cash items -11.09296M 1.29M - - -
Free cash flow -7.59380M -16.95903M -0.03660M -0.00294M -0.00619M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ATGGF
Actinogen Medical Limited		 - -% 0.0008 - - 15.41 18.91 177.64 -6.7326
NVO
Novo Nordisk A/S		 2.69 6.23% 45.88 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.60 3.69% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 15.16 3.36% 466.79 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 2.56 0.42% 612.50 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11ß-HSD1 enzyme that achieves target engagement in the brain for the treatment of Alzheimer's disease, major depressive disorder, fragile x syndrome, and other neurological diseases. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia.

Actinogen Medical Limited

109 Pitt Street, Sydney, NSW, Australia, 2000

Key Executives

Name Title Year Born
Dr. Steven G. Gourlay ), FRACP, M.B.A., MBBS (M.D., Ph.D. MD, CEO & Director 1960
Mr. Jeff Carter BFinAdmin, MAppFin Chief Financial Officer 1958
Ms. Tamara Miller Sr. VP of Product Devel. NA
Prof. Paul Rolan D.C.P.S.A., F.F.P.M., F.R.A.C.P., M.B.B.S., M.D. Chief Medical Officer NA
Mr. Michael Roberts Head of Investor Relations & Corp. Communications NA
Ms. Therese Russell Head of People & Infrastructure NA
Dr. Christian Toouli Head of Bus. Devel. NA
Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D., MAICD Company Sec. 1963
Dr. Steven G. Gourlay ), FRACP, M.B.A., MBBS (M.D., Ph.D. MD, CEO & Director 1959
Mr. William Edward Souter BCom, IPAA, LLB (Adel) Chief Financial Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.